Cargando…
Application of Wharton jelly-derived mesenchymal stem cells in patients with pulmonary fibrosis
Pulmonary fibrosis is a devastating disease that eventually leads to death and respiratory failure. Despite the wide range of drugs, including corticosteroids, endothelin antagonist, and pirfenidone, there is no effective treatment, and the only main goal of treatment is to alleviate the symptoms as...
Autores principales: | Saleh, Mahshid, Fotook Kiaei, Seyedeh Zahra, Kavianpour, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845364/ https://www.ncbi.nlm.nih.gov/pubmed/35168663 http://dx.doi.org/10.1186/s13287-022-02746-x |
Ejemplares similares
-
Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial
por: Saleh, Mahshid, et al.
Publicado: (2021) -
Differentiation of Wharton's Jelly Derived Mesenchymal Stem Cells into Insulin Producing Cells
por: Ranjbaran, Hossein, et al.
Publicado: (2018) -
Effects of Wharton's jelly-derived mesenchymal stem cells on chronic obstructive pulmonary disease
por: Cho, Jun Woo, et al.
Publicado: (2019) -
Effects of Wharton’s jelly-derived mesenchymal stem cells on neonatal neutrophils
por: Khan, Imteyaz, et al.
Publicado: (2014) -
Isolation and Characterization of Feline Wharton’s Jelly-Derived Mesenchymal Stem Cells
por: Seo, Min-Soo, et al.
Publicado: (2021)